Skip to main content
. Author manuscript; available in PMC: 2023 Apr 6.
Published in final edited form as: Hepatoma Res. 2023 Mar 17;9:7. doi: 10.20517/2394-5079.2022.85

Table 3.

Tumor characteristics of Pacific Island patients with HCC

PI-born (n = 92) US-born (n = 153) P value Unadjusted OR, 95%CI
Mean size of primary tumor (cm) 6.49 ( 5.01) 6.58 ( 4.84) P = 0.90
Size ≥ 5cm 44 (48%) 79 (52%) P = 0.58 0.86 (0.51–2.11)
Size ≥ 10cm 25 (27%) 37 (24%) P = 0.61 1.17 (0.65–2.11)
Multiple tumors 37 (40%) 52 (34%) P = 0.33 1.31 (0.77–2.23)
Bilateral tumors 14 (18%) 24 (17%) P = 0.92 1.04 (0.50–2.15)
Met Milan criteria 38 (41%) 65 (42%) P = 0.78 0.95 (0.56–1.61)
Cirrhosis 76 (84%) 107 (70%) P = 0.02 2.28 (1.17–4.45)
BCLC stage 0 1 (1%) 6 (4%) P = 0.22 0.26 (0.03–2.24)
A 30 (33%) 53 (35%) P = 0.70 0.89 (0.52–1.55)
B 36 (39%) 64 (42%) P = 0.63 0.87 (0.52–1.48)
C 11 (12%) 14 (9%) P = 0.52 1.33 (0.57–3.07)
D 14 (15%) 14 (9%) P = 0.16 1.76 (0.80–3.87)

HCC: Hepatocellular carcinoma; PI-born: Pacific Island-born; BCLC: barcelona clinic liver cancer.